Low 2016/17 season vaccine effectiveness against hospitalised influenza A(H3N2) among elderly: awareness warranted for 2017/18 season.

Autor: Rondy M; EpiConcept, Paris, France., Gherasim A; National Centre of Epidemiology, Institute of Health Carlos III, Madrid, Spain.; CIBER Epidemiología y Salud Pública, Institute of Health Carlos III, Madrid, Spain., Casado I; CIBER Epidemiología y Salud Pública, Institute of Health Carlos III, Madrid, Spain.; Instituto de Salud Pública de Navarra, IdiSNA, Pamplona, Spain., Launay O; Inserm, F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), CIC 1417, Paris, France.; Université Paris Descartes, Sorbonne Paris Cité, APHP, CIC Cochin-Pasteur, Paris, France., Rizzo C; Istituto Superiore di Sanità, Rome, Italy., Pitigoi D; University of Medicine and Pharmacy Carol Davila, National Institute for Research Cantacuzino, Bucharest, Romania., Mickiene A; Department of Infectious diseases of Lithuanian University of Health Sciences, Kaunas, Lithuania., Marbus SD; Centre for Epidemiology and surveillance of infectious diseases, Centre for Infectious disease control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands., Machado A; Epidemiology Research Unit, Epidemiology Department, National Health Institute Doutor Ricardo Jorge, Lisbon, Portugal., Syrjänen RK; Impact Assessment Unit, National Institute for Health and Welfare, Tampere, Finland., Pem-Novose I; Epidemiology Service, Croatian Institute of Public Health, Zagreb, Croatia., Horváth JK; Office of the Chief Medical Officer, Budapest, Hungary., Larrauri A; National Centre of Epidemiology, Institute of Health Carlos III, Madrid, Spain.; CIBER Epidemiología y Salud Pública, Institute of Health Carlos III, Madrid, Spain., Castilla J; CIBER Epidemiología y Salud Pública, Institute of Health Carlos III, Madrid, Spain.; Instituto de Salud Pública de Navarra, IdiSNA, Pamplona, Spain., Vanhems P; Infection Control and Epidemiology Unit, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France.; Emerging Pathogens Laboratory - Fondation Mérieux, Centre International de Recherche en Infectiologie, INSERM U1111, Centre National de la Recherche Scientifique (CNRS), UMR5308, Ecole Nationale Supérieure (ENS) de Lyon, Université Claude Bernard Lyon 1, Lyon, France.; Inserm, F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), CIC 1417, Paris, France., Alfonsi V; Istituto Superiore di Sanità, Rome, Italy., Ivanciuc AE; National Institute for Research Cantacuzino, Bucharest, Romania, Faculty of Biology, Bucharest University., Kuliese M; Department of Infectious diseases of Lithuanian University of Health Sciences, Kaunas, Lithuania., van Gageldonk-Lafeber R; Centre for Epidemiology and surveillance of infectious diseases, Centre for Infectious disease control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands., Gomez V; Epidemiology Research Unit, Epidemiology Department, National Health Institute Doutor Ricardo Jorge, Lisbon, Portugal., Ikonen N; Unit of Expert Microbiology, National Institute for Health and Welfare, Helsinki, Finland., Lovric Z; Epidemiology Service, Croatian Institute of Public Health, Zagreb, Croatia., Ferenczi A; Office of the Chief Medical Officer, Budapest, Hungary., Moren A; EpiConcept, Paris, France.
Jazyk: angličtina
Zdroj: Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin [Euro Surveill] 2017 Oct; Vol. 22 (41).
DOI: 10.2807/1560-7917.ES.2017.22.41.17-00645
Abstrakt: In a multicentre European hospital study we measured influenza vaccine effectiveness (IVE) against A(H3N2) in 2016/17. Adjusted IVE was 17% (95% confidence interval (CI): 1 to 31) overall; 25% (95% CI: 2 to 43) among 65-79-year-olds and 13% (95% CI: -15 to 30) among those ≥ 80 years. As the A(H3N2) vaccine component has not changed for 2017/18, physicians and public health experts should be aware that IVE could be low where A(H3N2) viruses predominate.
Databáze: MEDLINE